HLA editing was long considered impossible because any mismatch was thought to cause immune rejection. Rumagen's breakthrough was targeting an amino acid deep within the HLA protein's structure—the "bottom of the taco"—making the change invisible to T-cells and circumventing rejection.

A recent study highlights a patient with type 1 diabetes achieving sustained insulin independence after stem cell transplantation. This marks a significant shift from symptom management to a potential one-time cure, repairing the body's ability to produce insulin and moving healthcare from treatment to repair.

Instead of bespoke edits for each autoimmune disease, Rumagen developed "anchor editing," targeting a single, conserved amino acid across all relevant HLA alleles. This creates a unified platform, streamlining regulatory pathways with potential for an FDA platform designation and enabling expansion into rare diseases with economies of scale.

Coya's treatment is a combination therapy that addresses two problems simultaneously. One component increases the number of functional regulatory T-cells (Tregs) to control the immune system. The second component suppresses the underlying inflammation that would otherwise cause these newly boosted cells to become dysfunctional again, ensuring a more durable effect.

The company's confidence in aiming for a cure is supported by real-world evidence. Patients with autoimmune diseases who receive bone marrow transplants for cancer are often incidentally cured of their autoimmunity due to the new immune system's different HLA profile. Rumagen aims to replicate this outcome safely with an autologous approach.

Despite initial hype in oncology where business models struggled, cell therapy is finding a major new application in treating autoimmune diseases. By resetting the immune system, it can offer functional cures for debilitating conditions—a powerful and unexpected pivot for the technology platform.

The primary hurdle for the entire biologics field is enhancing the therapeutic index (efficacy vs. toxicity). Because most conditions like cancer and autoimmune disorders are 'diseases of self,' therapeutics often have on-target, off-tumor effects. This fundamental problem drives the need for innovations like masking and conditional activation.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.

Quell differentiates its CAR-Treg therapy by aiming to restore immune balance. Unlike B-cell depletion therapies (CAR-T), their approach uses CD19 on B-cells as an activation signal. This creates a local suppressive environment that 'chills' multiple pathogenic cell types (T-cells, B-cells, macrophages) instead of killing just one.